<DOC>
	<DOCNO>NCT02860780</DOCNO>
	<brief_summary>The main purpose study evaluate safety study drug prexasertib combination ralimetinib participant advance metastatic cancer .</brief_summary>
	<brief_title>A Study Prexasertib ( LY2606368 ) Combination With Ralimetinib Participants With Advanced Metastatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<criteria>Advanced metastatic cancer . Able swallow tablet . For Part B , need colon cancer nonsmall cell lung ( NSCLC ) cancer KRAS and/or BRAF mutation . Discontinued previous treatment cancer recover acute effect therapy . Active infection ( fungal , viral , bacterial ) . Active cancer brain spinal cord . Acute chronic leukemia . Serious heart condition . Disease require immunosuppressant therapy . Diagnosis inflammatory bowel disease . Major small bowel resection interfere body 's ability absorb oral medicine . Participated clinical trial investigate prexasertib ralimetinib . Pregnant breastfeeding . Other preexist condition medical history doctor explain .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>